AzTrials
AzTrials

Anxiety Related to the COVID-19 PandemicCORANCT04331106

Survey of the Anxiety Associated With the COVID-19 Pandemic

An observational study of Anxiety Related to the COVID-19 Pandemic, run by Charite University, Berlin, Germany at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study aims to systematically examine various aspects of the anxiety associated with the COVID-19 pandemic in Germany. The data collection is carried out online with longitudinal repeated measurements. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Anxiety Related to the COVID-19 Pandemic
What is being tested?
Online Questionnaire
How many people
7,500 participants
Where
1 siteGermany
Study dates
27 Mar 2020to Apr 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: General population in Germany

Who may be able to join

  • informed consent was given
  • age ≥ 18
  • able to complete the questionnaire in German
  • country of residence: Germany

Who cannot join

  • if at least one of the inclusion criteria is not met

Trial locations and contacts

1 site in 1 country.

Antonia Bendau, M.Sc.Psych. contact

+4930450517274

antonia.bendau@charite.de

Andreas Ströhle, Prof.Dr. contact

+4930450517217

andreas.stroehle@charite.de

Germany1 site, 1 recruiting

  • Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy

    Berlin, 10117

    +49 30 450 517 285, corona-angst@charite.de

    Recruiting

Other trials in Germany

About this study

Official title: Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany

The study aims to systematically examine various aspects of the anxiety associated with the COVID-19 pandemic in Germany. The data collection is carried out online with longitudinal repeated measurements.

Read the detailed description

The COVID-19 pandemic is currently one of the greatest challenges for numerous countries - also for Germany. In addition to its somatic and economic consequences, the psychological dimension of the Coronavirus pandemic is discussed increasingly and is visible in public life - e.g. in the "pandemic-caused experience of threat", "loss of control" and "panic" of multiple people. The study examines the phenomenon of this "corona-related anxiety" in terms of epidemiological, clinical and psychosocial characteristics. It is investigated how "corona anxiety" affects people who already have an anxiety disorder or other mental illnesses as well as formerly mentally healthy people. It is also examined how media reporting and personal consequences of COVID-19 are connected with corona-related anxiety and if there is a need for therapeutic support regarding corona-related anxiety.

To answer these questions a longitudinal online survey targeting the general population in Germany is carried out. The survey takes place all three weeks as long as the pandemic lasts and ends with one follow-up one year later.

Being tested
Online Questionnaire
Keywords
Anxiety, Pandemic, Corona-Virus, SARS-CoV-2, Corona, Covid-19, Public Health, Mental Health, Health, Mental Disorders
Medical subject headings
Anxiety Disorders, COVID-19, Psychological Well-Being, Mental Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Online QuestionnaireDiagnostic test

    Online Questionnaire via SoSci Survey

Study groups in NCT04331106
Study groupRoleWhat they receive
Population in GermanyReasonably large and representative sample of the general population in Germany
Receives: Diagnostic Test: Online Questionnaire

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Characteristics of COVID-19-related anxiety

    To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.

    Measured: 1 day

  2. COVID-19-related anxiety symptoms

    Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.

    Measured: 1 day

Secondary outcomes (7)

  1. Self-efficacy and coping with COVID-19

    Self-efficacy and coping with the COVID-19 pandemic are measured with 13 self created items. Values ranging from 1 to 6; higher scores indicate a better outcome (except inverted items).

    Measured: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months

  2. Consequences of COVID-19 in the last three weeks.

    Personal consequences of the COVID-19 pandemic in the last three weeks are collected with five self-created items.

    Measured: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months

  3. General Illness Attitude

    General illness attitudes are measured with 3 subscales (Worry about illness; Thanatophobia; Bodily preoccupations) of the German version of the Illness Attitude Scales (IAS) by Hiller \& Rief (2004). 9 Items; values ranging from 1 to 5, higher scores indicate a worse outcome.

    Measured: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months

  4. Media reporting

    Frequency, effects and formats of consumed media related to COVID-19 are measured with 5 self created items.

    Measured: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months

  5. Ultra-brief screening scale for anxiety and depression

    To screen for general anxiety and depressive symptoms the German version of the Patient Health Questionnaire-4 (PHQ-4) by Löwe (2015) is used. 4 items; values ranging from 0 to 3, higher scores indicate a worse outcome.

    Measured: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months

  6. Change in characteristics of COVID-19-related anxiety

    To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.

    Measured: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months

  7. Change in COVID-19-related anxiety symptoms

    Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.

    Measured: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2020
  2. Study start27 Mar 2020
  3. Primary completionApr 2022 (estimated)
  4. Study completionApr 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
7,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04331106
Sponsor's protocol ID
EA1/071/20
Acronym
CORA
Status last verified
Jan 2021
First submitted
27 Mar 2020
Last updated
27 Jan 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Bendau A, Petzold MB, Strohle A, Plag J. Viral Transmission? A Longitudinal Study of Media Use and Its Relation to Mental Strain During the First 2 Years of the COVID-19 Pandemic. Int J Behav Med. 2025 Apr;32(2):214-226. doi: 10.1007/s12529-024-10293-3. Epub 2024 May 20.

    PubMed 38769221

  • Bendau A, Petzold MB, Plag J, Asselmann E, Strohle A. Illness anxiety predicts higher mental strain and vaccine willingness-A nine-wave longitudinal study during the first 1.5 years of the COVID-19 pandemic in Germany. Stress Health. 2023 Dec;39(5):1137-1147. doi: 10.1002/smi.3255. Epub 2023 May 9.

    PubMed 37158010

  • Olsson A, Olsson M, Fedorowski A, Hagell P, Wictorin K. The Orthostatic Hypotension Questionnaire in Swedish tested in patients with parkinsonism. Brain Behav. 2020 Sep;10(9):e01746. doi: 10.1002/brb3.1746. Epub 2020 Jul 7.

    PubMed 32633094

Questions about this trial

What is this clinical trial studying?

An observational study of Anxiety Related to the COVID-19 Pandemic, run by Charite University, Berlin, Germany at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Antonia Bendau, M.Sc.Psych. (+4930450517274, antonia.bendau@charite.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Characteristics of COVID-19-related anxiety (time frame: 1 day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04331106, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in